Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 80.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,913 shares of the biotechnology company's stock after selling 283,560 shares during the quarter. CenterBook Partners LP's holdings in Arrowhead Pharmaceuticals were worth $852,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,628 shares during the period. GF Fund Management CO. LTD. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $49,000. CWM LLC lifted its position in shares of Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 2,523 shares during the period. KBC Group NV lifted its position in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after buying an additional 2,132 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter valued at $133,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on ARWR shares. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Trading Down 11.1%

ARWR stock traded down $2.09 during trading on Friday, reaching $16.76. 3,012,546 shares of the stock were exchanged, compared to its average volume of 1,580,857. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $29.86. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -11.97, a P/E/G ratio of 19.71 and a beta of 0.93. The business has a 50 day moving average price of $16.34 and a 200-day moving average price of $16.32. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter in the prior year, the firm earned ($1.02) EPS. On average, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.